ELDN Eledon Pharmaceuticals, Inc.: institutional ownership and insider trading
165 funds reported holding $194M of Eledon Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $20.0M, with 48 new positions and 9 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
ELDN revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$31.6M, EPS -0.27
- Quarter ended Mar 31, 2026: revenue n/a, net income −$39.0M, EPS -0.33
- Quarter ended Dec 31, 2025: revenue n/a, net income −$10.4M, EPS -0.10
- Quarter ended Sep 30, 2025: revenue n/a, net income −$17.5M, EPS -0.21
Famous investors holding ELDN
- Izzy Englander (Millennium Management): $3.86M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $2.01M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $792K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $130K, 0.0% of the portfolio
Largest institutional holders of ELDN
- BVF INC/IL — $24.8M
- BlackRock, Inc. (BLK) — $20.2M
- Defilade Capital Management, L.P. — $13.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $13.5M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $9.89M
- Ensign Peak Advisors, Inc — $8.28M
- GEODE CAPITAL MANAGEMENT, LLC — $7.71M
- Catalio Capital Management, LP — $6.68M
- STATE STREET CORP (STT, STT-PG) — $6.39M
- Zimmer Partners, LP — $6.29M
5%+ owners
- BVF PARTNERS L P/IL: 10.0% (Schedule 13G/A, filed May 15, 2026)
- BlackRock, Inc.: 5.8% (Schedule 13G, filed Apr 27, 2026)
- Vanguard Capital Management: 5.1% (Schedule 13G, filed Jul 31, 2026)